Evaluation of [123I] AV94 and SPECT in Subjects With Alzheimer Disease in Comparison to Healthy Subjects
Status:
Terminated
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
The main objectives of this proposal are as follows:
To assess the dynamic uptake and washout of 123-I AV94, a potential imaging biomarker for
β-amyloid burden in brain, using single photon emission computed tomography (SPECT) in
similarly aged healthy controls and Alzheimer's (AD) subjects
To perform blood metabolite characterization of 123-I AV94 in healthy and AD subjects to
determine the metabolic fate and nature of metabolites in assessment of 123-I AV94 as a
single photon computed tomography (SPECT) brain imaging agent
Evaluate the test/retest reproducibility of 123-I AV94 and SPECT in AD subjects and healthy
controls